Advances in the Treatment of Drug-Resistant Pediatric Epilepsy

Area of Science:

• Neurology
• Pediatric Epilepsy
• Pharmacology

Background:

• Epilepsy is a prevalent neurological disorder impacting children and adults, causing significant morbidity.
• Established antiseizure medications control epilepsy in two-thirds of patients, but a substantial portion remains treatment-resistant.
• Pediatric epilepsy syndromes, such as Dravet's and Lennox-Gastaut's syndromes, present unique management challenges.

Purpose of the Study:

• To review recent advancements in managing treatment-resistant epilepsy specifically in pediatric patients.
• To highlight novel pharmaceutical and device-based therapeutic options for pediatric epilepsy.

Main Methods:

• Review of recent publications and U.S. Food and Drug Administration (FDA) approvals.
• Focus on pharmaceutical interventions (fenfluramine, cannabidiol, stiripentol) and neurostimulation devices.

Main Results:

• Fenfluramine and cannabidiol show efficacy in pediatric patients, including those with Dravet's and Lennox-Gastaut's syndromes.
• Stiripentol is now an accessible option for Dravet's syndrome following FDA approval.
• Implanted neurostimulation devices (responsive neurostimulation, deep brain stimulation) demonstrate efficacy in adults and hold potential for pediatric use.

Conclusions:

• Emerging pharmaceutical treatments offer new avenues for managing treatment-resistant pediatric epilepsy.
• Neurostimulation devices represent a promising future direction for refractory epilepsy in children.
• These advancements provide critical updates for clinicians managing complex pediatric epilepsy cases.